Advertisement

Advertisement
COVID-19

Study Examines Potential Benefits of a Fourth COVID-19 Vaccination for Patients With Cancer

A research team led by Matthias Preusser, MD, PhD, Professor of Medical Oncology and Head of the Clinical Division of Oncology at the Medical University of Vienna...

Genomics/Genetics

Cancer Phenotypes Associated With Germline CHEK2 Variants

In a retrospective cohort study reported in JAMA OncologyBrittany L. Bychkovsky, MD, MSc, and colleagues analyzed the spectrum of cancer...

Skin Cancer

M14TIL: Tumor-Infiltrating Lymphocytes for Patients With Advanced Melanoma

A novel treatment strategy with personalized cell therapy significantly improved progression-free survival compared to standard immunotherapy...


Advertisement
Skin Cancer
Immunotherapy

SWOG S1801: Neoadjuvant and Adjuvant Pembrolizumab for Patients With Stage IIIB to IV Melanoma

Patients with high-risk melanoma who received the anti–PD-1 therapy pembrolizumab both before and after surgery to remove cancerous tissue...

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement




Lung Cancer
Issues in Oncology

Debora S. Bruno, MD, on NSCLC: Racial Disparities in Biomarker Testing and Clinical Trial Enrollment

Issues in Oncology

Predictors of Emergency Department Visits After a New Diagnosis of Cancer

In a retrospective cohort study reported in JCO Oncology Practice, Hong et al found that prior frequent emergency department use was the strongest predictor of postdiagnosis emergency department visits among patients with a new diagnosis of cancer. Study Details The study involved data from...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Issues in Oncology

Matthew G. Vander Heiden, MD, PhD, and Karen H. Vousden, PhD: A Conversation About the Role of Diet in Cancer

Prostate Cancer

Novel PSMA-Targeted Radiotherapy Improves Radiographic Progression-Free and Overall Survival in Metastatic Prostate Cancer

Lutetium-177–PSMA-617 (Lu-177–PSMA-617)—an investigational radioligand therapy—significantly improved radiographic progression-free survival and overall survival when added to standard of care compared with standard of care alone for men with metastatic castration-resistant prostate cancer whose...

Bladder Cancer
Immunotherapy

CheckMate 274: Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma

As reported in The New England Journal of Medicine by Dean F. Bajorin, MD, and colleagues, an interim analysis of the phase III CheckMate 274 trial has shown improved disease-free survival with adjuvant nivolumab vs placebo among all patients with high-risk muscle-invasive urothelial carcinoma who...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Issues in Oncology

Narjust Duma, MD, and Gladys I. Rodriguez, MD, on A First for Hispanic Women: Formation of a YIA for Latinas

Solid Tumors
Genomics/Genetics
Immunotherapy

Pertuzumab/Trastuzumab Demonstrates Activity in Tissue-Agnostic Trial for Patients With HER2-Positive Tumors

Results from the phase II MyPathway basket trial found that the HER2-targeted therapies pertuzumab and trastuzumab demonstrated durable activity in patients with a wide variety of tumors marked by HER2 amplification or overexpression, although responses were limited in those with KRAS mutations....

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...